5 December 2024
DLA Piper advises Regor Pharmaceuticals in US$850 million sale of CDK inhibitors to Genentech
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Adam Brenner Lead | DLA Piper | Partner | Not stated | New York |
| Jonathan Klein Lead | DLA Piper | Partner | Not stated | New York |
| Alexandra Kamerling | DLA Piper | Partner | Not stated | London |
| Paolo Morante | DLA Piper | Partner | Not stated | New York |
1 more lawyer on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 850m (US$850 million)
- What the figure measures
- Total transaction value
- Client
- Regor PharmaceuticalsSell-side
- Counterparties
- Genentech (Buy-side)